MedTrace Logo

Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer

NCT05676190 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-01-09

No results posted yet for this study

Summary

This project plans to use CIK combined with chemotherapy, immunotherapy and targeted therapy to treat CRC patients, so as to explore the effectiveness of CIK treatment and the CRC subtypes more suitable for CIK treatment, thereby improving the survival rate and quality of life of CRC patients.

Conditions

Interventions

COMBINATION_PRODUCT

CIK combined with chemotherapy group

Combination of chemotherapy and autologous cytokine induced killer cells

COMBINATION_PRODUCT

CIK combined immunotherapy group

Combination of immunotherapy and autologous cytokine induced killer cells

COMBINATION_PRODUCT

CIK combined targeted therapy group

Combination of targeted therapy and autologous cytokine induced killer cells

COMBINATION_PRODUCT

CIK in combination with other therapies

CIK combined with any two or three of them (i.e. chemotherapy, immunotherapy and targeted therapy)

Sponsors & Collaborators

  • ShiCang Yu

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-09
Primary Completion
2026-12-30
Completion
2027-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05676190 on ClinicalTrials.gov